What You Will Do (Key Responsibilities)
- Utilize a combination of industry-standard and proprietary AI-powered CADD tools to guide small molecule drug discovery programs across a diverse target portfolio, including novel targets with limited chemical precedents.
- Use approaches like virtual screening, molecular simulation, and potency and ADMET prediction to support key decision-making in drug discovery efforts.
- Collaborate closely with medicinal chemists in molecular design and the development of project-specific computational approaches.
- Act as a cross-team connector, effectively communicating between our computational chemistry and medicinal chemistry teams to ensure seamless information flow and collaborative decision making.
- Adapt to a fast-paced environment where innovation and quick iteration are encouraged.
What you’ll bring
- PhD in Computational Chemistry, Structural Biology, or a related field. This particular role may also be suitable for PhD-level scientists with degrees in organic or medicinal chemistry with extensive experience in the lab, who have transitioned into industry roles in CADD.
- Deep understanding of structure-based drug design and protein-ligand interactions.
- Proficiency with industry-standard CADD tools such as MOE, PyMOL, and Schrodinger Suite.
- Minimum of 5+ years of industry experience as a CADD scientist in pharma or biotech, with hands-on experience in active drug discovery programs.
What we offer
- Competitive Pay
- Health Care Plans (including Medical, Dental, and Vision, fully covered for the employees)
- Stock Option Eligibility
- 401(k) Plan
- Open PTO Policy
- Paid Company Holidays
- Free lunch and snacks at our offices
Similar Jobs
.png)
What We Do
Genesis Therapeutics is unifying AI and biotech to accelerate and optimize drug discovery.
We pioneer novel deep learning and molecular simulation techniques to accelerate the development of new medicines.
Genesis raised its $52M Series A from top tech + biotech investors, Andreessen Horowitz, Rock Springs, and T. Rowe Price.
Story: https://techcrunch.com/2020/12/02/genesis-therapeutics-raises-52m-a-round-for-its-ai-focused-drug-discovery-mission/
We deploy our technology to accelerate a pipeline of several internal drug programs.
Furthermore, Genesis has announced two significant, multi-target collaborations with Genentech and with Eli Lilly, the latter of which entailed a $20M upfront payment with a $670M total deal size.
Now we are scaling the team and technology to support many more programs in parallel as well as increasingly difficult protein targets.
We currently have a team (genesistherapeutics.ai/company.html#team) of about 35 people, split 50/50 between our ML / software team and our biochem team of veteran drug hunters in our own wetlab space. Our ML + software engineers are top-notch -- many graduates from MIT, UC Berkeley, Stanford. Previously worked at OpenAI, Google, Facebook, MemSQL, Jane Street, Dropbox, etc.
We're recruiting pure ML research scientists + software engineers (no bio or chem experience expected) to further our core AI platform as well as scale our drug pipeline.
Likewise, we have several openings in chemistry and biology to join our team of biotech + pharma veterans who are deploying the Genesis ML platform to discover novel drug candidates.
Please apply on our website, or feel free to reach out via email directly: [email protected]
